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sults: dhUCM cells appeared as binucleated cells with exten-
sive cytoplasmic processes. These differentiated cells were 
F-actin and myogenin positive. Thirty days after LAD liga-
tion, left ventricular ejection fraction and the percentage of 
fractional shortening improved significantly in cell-receiving 
animals. In addition, the amount of scar tissue was signifi-
cantly reduced in hUCM and dhUCM groups compared to MI 
group (p  ! 0.05). These parameters were comparable be-
tween hUCM and dhUCM groups. Histopathological evalua-
tions revealed that some engrafted cells adjacent to and re-
mote from the MI area expressed troponin-I, F-actin and con-
nexin43.  Conclusion: These findings demonstrated the 
potential therapeutic use of either differentiated or undif-
ferentiated hUCM cells in treatment of heart failure condi-
tions.  Copyright © 2011 S. Karger AG, Basel 
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 Abstract 
 Objectives: Human umbilical cord mesenchymal cells 
(hUCM) can be easily obtained and processed in a laboratory. 
These cells may be considered as a suitable source in the 
repair of heart failure diseases. We, therefore, examined 
whether these cells may contribute to heart regeneration 
following an acute experimental myocardial infarction (MI). 
 Methods: MI-induced animals received 5  ! 10 6 hUCM cells, 
5  ! 10 6 5-azacytidine-treated cells (dhUCM), or PBS alone, 
subepicardially. A group of animals with MI and no other for-
mer intervention served as controls. dhUCM cells were as-
sessed for F-actin, myogenin and troponin-I expression.  Re-
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 Introduction 
 Myocardial infarction (MI), a common disease in the 
industrialized world, results in loss of cardiomyocytes 
leading to heart failure. To replace lost cardiomyocytes af-
ter infarction, cell transplantation has been suggested as a 
potential therapy  [1] . Autologous adult stem cells are im-
munologically compatible and can be collected from a va-
riety of sources including bone marrow  [2–4] , and there is 
no ethical issue relevant to their use. Meta-analyses have 
shown the safety of this treatment and a slight but signifi-
cant improvement in left ventricular (LV) ejection fraction 
(EF) and a decrease in infarct size  [5] . However, not all 
clinical trials and experimental studies could demonstrate 
a significant improvement in heart function following 
mesenchymal stromal cell (MSC) transplantation  [6, 7] .
 In addition to bone marrow as a common source of 
mesenchymal cells  [8] , multipotent MSC can be collected 
from extraembryonic tissues including placental and 
umbilical cord blood (UCB)  [9] as well as umbilical cord 
matrix (UCM)  [10] , which needs to be given more atten-
tion. Studies have indicated the feasibility of MSCs de-
rived from extraembryonic tissues  [11] , including UCB 
cells for the repair of ischemic heart diseases  [12–14] . 
However, there are conflicting data in the literature re-
garding the use of UCB cells for the repair of ischemic 
myocardium in different animal models  [15, 16] . Several 
studies have evaluated the effects of UCBs on MI animal 
models. However, the feasibility of human UCM (hUCM) 
cells for the repair of acute MI needs to be explored. The 
hUCM cells have the advantages of being obtained by 
noninvasive procedures, harvesting done easily in labo-
ratory and, most often, not triggering immune response 
in host animals  [17] . Weiss et al.  [18] demonstrated that 
porcine UCM cells survive, migrate and express markers 
for mature neurons when transplanted into a rat brain. 
Importantly, the implanted cells showed no evidence of 
forming teratomas. In vitro evidences support the idea 
that UCM cells could differentiate into cardiomyocytes 
by treating them with 5-azacytidine or by culturing them 
in cardiomyocyte-conditioned medium  [19] . Also, trans-
plantation of hUCM cells into the injured anal sphincter 
improved the sphincter function after two weeks  [20] , in-
dicating the potential of hUCM cells to transdifferentiate 
into muscle cells in vivo.
 Here, we describe the feasibility of hUCM cell surviv-
al, possible in vitro differentiation into adipogenic, osteo-
genic and cardiogenic cell lineage, contribution to heart 
function and possible trans-differentiation into cardio-
myocytes in an MI-induced rabbit model.
 Materials and Methods  
 Chemicals 
 Chemicals were purchased from Sigma-Aldrich Chemical 
Company, St. Louis, Mo., USA unless stated otherwise. 
 Isolation and Culture of hUCM Cells 
 Human umbilical cords were obtained after delivery and col-
lected in HBSS, with written consent provided by the mothers. 
The umbilical cords were diced into fragments and then cultured 
in tissue culture plates containing DMEM-F12 supplemented 
with 15% FBS (Gibco), 100 U/ml penicillin, 60   g/ml streptomy-
cin (complete medium) in a humidified 37   °   C incubator with 5% 
CO 2 in the air. Cells at confluence of  1 90% were either subcul-
tured or cryopreserved for further use. 
 Phenotype Analysis of hUCM Cells 
 hUCM cells were cultured to confluence until some colonies 
appeared among the propagated cells. The colonies were stained 
by an alkaline phosphatase kit (R-87; Sigma). Also, 1  ! 10 6 hUCM 
cells/ml were cultured in hanging drops (50   l each), and three 
days later, colony formation was assessed. These colonies were 
also examined for alkaline phosphatase activity. 
 Flow Cytometric Analysis of hUCM Cells 
 A set of antibodies against hUCM cells was selected as report-
ed in the previous studies  [17] . 1  ! 10 5 cells/ml hUCM cells were 
fixed with 4% paraformaldehyde and incubated with 5% normal 
goat serum in PBS. Cells were labeled by the following antibodies: 
FITC-conjugated anti-CD44 (Chemicon), FITC-conjugated anti-
CD34 (Chemicon), FITC-conjugated anti-CD45 (Ediscience), 
PE-conjugated anti-CD90 (Dako), and PE-conjugated anti-
CD105 (R&D Systems) for 1 h. Cells were also incubated with 
anti-CD117 and anti-Oct4 for 1 h, followed by FITC-conjugated 
goat anti-mouse IgG (R&D Systems) for 45 min. The cells were 
analyzed using FACSCalibur (Becton Dickinson) machine and 
WinMDI Cellquest software. 
 Adipogenic and Osteogenic Differentiation 
 To evaluate the differentiation potential of hUCM cells as a 
mesenchymal stem cell, these cells were induced to differentiate 
into adipocyte and osteocyte cells. Adipogenic differentiation 
was induced by the culture of hUCM cells in complete medium 
supplemented with 10% FBS and 100 n M dexamethasone. For os-
teogenic differentiation, the hUCM cells were cultured in osteo-
genic differentiation medium containing complete medium, 10 
n M   -glycerophosphate, 80   g/ml ascorbic acid and 10 n M dexa-
methasone. Twenty-one days later, the cultures were fixed by 4% 
paraformaldehyde in PBS and stained with Oil red and Alizarin 
Red S (40 nm) for the detection of adipogenic and osteogenic dif-
ferentiation, respectively. The dish area was observed with a light 
microscope equipped with a phase-contrast apparatus and the 
cells cultivated in basal medium served as control.
 Induction of Cardiogenic Differentiation 
 The hUCM cells were incubated for 24 h in serum-free DMEM-
F12 containing 3   M 5-azacytidine  [21] . The medium was then 
changed to complete medium. Cells were maintained in the same 
culture medium for two to three weeks. The medium was re-
freshed every 2–4 days.
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 Immunocytochemistry  
 5-Azacytidine-treated cells (dhUCM) and hUCM cells as con-
trols were fixed in 4% paraformaldehyde in PBS, incubated with 
5% normal goat serum in PBS, treated with 3% H 2 O 2 in PBS, and 
were incubated with F-actin (Dako; 1: 400), cardiac troponin-I 
(Chemicon; 1: 2,000) and myogenin (Dako; 1: 50) for 45 min, fol-
lowed by incubation in EnVision TM (Dako). Cells were evaluated 
under a light microscope.
 Cell Preparation 
 Seventy-two hours before cell transplantation, the hUCM and 
dhUCM cells were incorporated with 10   mol 5-bromo-2  -
deoxyuridine (BrdU; Chemicon) for 48 h  [22] ; 5  ! 10 6 viable cells 
were resuspended in 50   l PBS, and were transplanted subepicar-
dially at the periphery of the infarcted area. 
 MI and Cell Transplantation 
 Thirty-five adult female New Zealand white rabbits (weight 
range 2.25–3.75 kg; Razi institute, Karaj, Iran) that withstood sur-
gical procedures were enrolled in this study. After echocardiog-
raphy, the animals were divided into five groups: (1) intact group 
(n = 7); (2) control group (n = 7) consisting of MI model; (3) PBS 
group (n = 7); (4) hUCM group (n = 7); (5) dhUCM group (n = 7) 
consisting of MI model with PBS, hUCM and dhUCM cells in-
jected into the periphery of MI region, respectively. 
 Animals were anesthetized with sodium pentobarbital (30 
mg/kg, intraperitoneally), were mechanically ventilated, and 
their hearts were exposed by means of a left thoracotomy through 
the fifth intercostal space. The proximal end of the LAD artery 
was ligated with a 6/0 silk suture. After 1 h of ligation, animals in 
PBS, hUCM and dhUCM groups received 50   l PBS, 5  ! 10 6 
hUCM cells and 5  ! 10 6 dhUCM cells, respectively. Cells were 
injected subepicardially by a 28-gauge needle attached to an insu-
lin syringe to the border of cyanotic area. Cyclosporine A (10 mg/
kg, subcutaneously) was given 24 h before the cell therapy and 
once daily, thereafter. The investigation was approved by the local 
ethics committee at Kerman University of Medical Sciences, Ker-
man, Iran.
 Transthoracic Echocardiography 
 Transthoracic echocardiography was performed using an 
echocardiographic instrument (Vivid3; General Electric) provid-
ed with a 5-MHz linear transducer, 5 and 30 days after MI to mea-
sure cardiac function in each group. A blinded cardiologist per-
formed transthoracic echocardiographic evaluations on the rab-
bits. Left-ventricular end-diastolic dimension (LVEDD) and 
left-ventricular end-systolic dimension (LVESD) were derived 
from two-dimensionally targeted M-mode tracings obtained 
along the parasternal long-axis view of the left ventricle at the 
papillary muscle level. Fractional shortening (FS) of the LV (LVFS 
(%) = [(LVEDD – LVESD)/LVEDD]  ! 100) and LVEF were calcu-
lated automatically by the echo equipment. 
 General Pathology and Immunohistochemistry Studies 
 Rabbits were killed by an overdose of pentobarbital, the hearts 
were then removed, rinsed in PBS and fixed in 10% buffered form-
aldehyde solution. 5-  m-thick sections were prepared from in-
farcted areas for hematoxylin and eosin as well as immunohisto-
chemistry (IHC) studies. Three different sections were randomly 
chosen from the infarcted area and the following parameters were 
assessed: number of small vessels, number of lymphocytes, num-
ber of fibroblasts, amount of scar tissue (0–3 scale) and severity of 
chronic inflammation (0–3 scale). For IHC studies, the slides were 
blocked in 5% normal goat serum and incubated overnight at 4  °  C 
with primary antibodies against BrdU (Abcam; 1: 40), troponin-I 
(Chemicon; 1: 2,000) and connexin43 (Abcam; 1: 250). The cells 
were then incubated with fluorescent Alexa-fluor  594 goat anti-
mouse secondary antibody (Molecular Probes; 1: 400) for 1 h for 
detection of troponin-I- and connexin43-positive cells, and sub-
sequently incubated with Alexa-fluor  647 secondary antibody 
(Molecular Probes; 1: 400) to detect BrdU-positive cells. The slides 
were also incubated with the primary antibody against connex-
in43 (Abcam; 1: 250) for 24 h at 4  °  C followed by Alexa-fluor  594 
goat anti-mouse secondary antibody (Molecular Probes; 1: 400) 
and hematoxylin for the background staining. To label the cells 
with human origin, mouse primary antibody to human specific 
nuclear antigen (abDSerotec; 1: 100) was followed by fluorescein 
isothiocyanate-conjugated goat anti-mouse antibody (Sigma-Al-
drich; 1: 100) and DAPI (Sigma-Aldrich). To detect F-actin-posi-
tive cells in the transplanted samples, the same procedure for IHC 
was applied to the slides after preparing the slides in Tris buffer 
(pH 7) for 10 min. The images were taken using an Olympus IX71 
inverted fluorescent microscope equipped with a digital camera 
(DP72; Olympus). 
 Statistical Analysis 
 Data are presented as means  8 SEM. The echocardiographic 
data were compared by oneway ANOVA, followed by post hoc 
Tukey-Kramer’s test, after normality assumption. Statistical com-
parison of histopathologic postsacrifice data was performed us-
ing Kruskal-Wallis test followed by the Mann-Whitney test after 
Bonferroni adjustment. 
 Results 
 hUCM Culture and Cell Marker Expression 
 The primary isolates were heterogeneous, with fibro-
blast-like cells possessing short and long processes and 
small round cells with a relatively high nuclear-to-cyto-
plasm ratio ( fig.  1 a). Individual cells propagated easily 
and formed colonies after being confluent  1 90% ( fig. 1 b). 
The hUCM cells expressed alkaline phosphatase after 
colony formation in culture plates ( fig. 1 c) and hanging 
drops ( fig. 1 d). Adipogenic ( fig. 1 e) and osteogenic ( fig. 1 f) 
differentiation was confirmed 21 days later. The hUCM 
cells were positive for mesenchymal stem cell markers, 
CD44, CD105, CD90, negative for CD34, CD45 and 
CD117, and slightly (4%) positive for Oct-4 ( fig. 2 ). 
 Cardiogenic Differentiation of hUCM Cells  
 We treated the hUCM cells with 5-azacytidine to in-
duce the differentiation of hUCM cells into cardiomyo-
cyte-like cells  [23] . Treated cells retained a mesenchymal 
phenotype with some binucleated cells among them 
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( fig. 3 a). Colonies of 5-azacytidine-treated cells expressed 
F-actin ( fig. 3 b). After an extended culture period, hUCM 
cells transformed into flat, large cells strongly positive for 
F-actin ( fig. 3 c). Moreover, some cells had a positive reac-
tion with myogenin ( fig. 3 d) and a negative reaction with 
troponin-I. Some cells in the control group were F-actin 
positive, but none were troponin-I and myogenin posi-
tive. 
 Evaluation of Myocardial Function 
 Five days after LAD ligation, LVEF decreased effi-
ciently in all LAD-ligated animals with no significant 
difference among the MI groups, and a significant de-
crease (p  ! 0.01) compared with the intact group ( fig. 4 ). 
Thirty days after LAD ligation, LVEF increased signifi-
cantly (p  ! 0.05) in hUCM and dhUCM groups compared 
with PBS and MI groups. The rise in LVEF was also sig-
nificantly higher (p  ! 0.05) in the hUCM and dhUCM 
groups compared with the intact, MI and PBS groups 
( fig. 4 ). Although the rise in LVEF was higher in dhUCM 
group, it was not significantly different from hUCM 
group. LVFS also significantly improved (p  ! 0.05) in the 
hUCM and dhUCM groups compared with PBS and MI 
groups ( table 1 ).
 Immunohistochemical Evaluations 
 Thirty days after transplantation, BrdU-incorporated 
cells were observed in the transplanted area ( fig.  5 a). 
Transplanted cells were HNA positive, indicating the hu-
man origin of transplanted cells in the rabbit myocardi-
um ( fig. 5 b). Some transplanted cells were troponin-I and 
F-actin positive. Besides, clusters of engrafted cells were 
observed in a remote distance from the transplantation 
site ( fig.  5 c, d;  6 c, e). Double staining revealed some 
BrdU+/troponin-I+ cells in the MI area adjacent to the 
normal myocardium ( fig. 5 e, f).
100 µm
100 µm
100 µm
100 µm
100 µm
100 µm
a b
c d
e f
 Fig. 1. The hUCM cells retained a fibro-
blastic cell shape with numerous cytoplas-
mic processes ( a ). These cells formed nu-
merous colonies ( b ) that stained positively 
by alkaline phosphatase in culture plates 
( c ) and hanging drops ( d ). These cells un-
derwent adipogenic ( e ; right-side image 
shows oil red staining and left-side image 
is a phase-contrast image) and osteogenic 
( f ; phase-contrast image showing deposi-
tion of minerals in red) differentiation fol-
lowing appropriate induction. Color refers 
to the online version. 
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 Fig. 2. The hUCM cells were positive for mesenchymal stem cell markers CD44, CD105 and CD90, negative for 
hematopoietic markers CD34 and CD45, negative for CD117 and slightly positive for Oct-4 as an embryonic 
stem cell marker. 
100 µm
50 µm
100 µm
100 µm
a b
c d
 Fig. 3. Treatment of hUCM cells with 
5-azacytidine resulted in some binucleate 
cells (arrows) with extended cytoplasmic 
processes ( a ), F-actin-positive clusters ( b ) 
and also individual cells ( c ). The treated 
cells showed positive reaction with myo-
genin (short arrows,  d ). 
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 The grafted cells also demonstrated to express gap-
junction protein connexin43 next to the host myocardi-
um and among the engrafted cells ( fig. 6 f).
 Histopathologic Evaluations  
 The scar tissue was more abundant in MI (2.29  8 
0.42) and PBS (1.46  8 0.49) than hUCM (0.71  8 0.35) 
and dhUCM (0.57  8 0.3) groups ( fig. 6 a, b;  table 2 ). The 
number of fibroblasts (89  8 44.7 and 77  8 33.2 in hUCM 
and dhUCM groups, respectively) and the severity of 
chronic inflammation (0.86  8 0.14 and 1 in hUCM and 
dhUCM groups, respectively) decreased in the hUCM 
and dhUCM groups, but no significant difference was ob-
served among the cell-treated animals compared with 
PBS and MI groups ( table 2 ). Some viable engrafted cells 
were detected in the MI area interposed between the nor-
mal myocardial cells ( fig. 6 c), and remote from it ( fig. 6 e). 
 Discussion 
 This study demonstrated that subepicardial engrafted 
hUCM and dhUCM cells could improve experimentally 
infarcted myocardium function after 30 days. While 
there was only weak evidence of transdifferentiation of 
engrafted cells into cardiomyocyte cells, and the presence 
of engrafted cells in the vicinity of cell-transplanted zone, 
hUCM and dhUCM cells have significantly improved left 
ventricle contractile function. Transplantation of hUCM 
cells also advantageously influenced scar tissue forma-
tion and the number of fibroblasts, while inflammatory 
reactions were minimized in infarcted hearts following 
cell engraftments. An ideal source of donor cells for car-
diovascular diseases therapy should be easily collected 
Table 1. E chocardiography results in different groups (n = 7)
Time point and parameter Intact Sham PBS hUCM dhUCM
5 days after LAD ligation and cell transplantation 
LVFS% 48.183.9 28.383.6 32.683.2 27.183.7 26.884.4
LVEDD, cm 1.4280.21 1.2980.15 1.2280.10 1.2280.12 1.1280.08
LVESD, cm 0.7480.16 0.9280.10 0.8180.06 0.8780.07 0.8280.08
30 days after LAD ligation and cell transplantation
LVFS% 42.380.22 29.682.7 28.482.1 39.482.2* 38.883.1*
LVEDD, cm 1.3280.12 1.5880.22 1.2880.15 1.2680.08 1.2780.07
LVESD, cm 0.7680.07 1.1180.15 0.9280.11 0.7680.04 0.7980.07
V alues are means 8 SEM. LAD = Left descending artery; LVFS% = left-ventricular fractional shortening; LVEDD = left-ventric-
ular end-diastolic dimension; LVESD = left-ventricular end-systolic dimensions. * p < 0.05 compared to PBS.
–20.00
–10.00
0
10.00
20.00
30.00
40.00
Intact Sham PBS
Experimental groups
M
ea
n
 c
h
an
g
e 
in
 L
V
EF
60.00
80.00
40.00
100.00
20.00
0
M
ea
n
 L
V
EF
hUCM dhUCM
Intact Sham PBS
Experimental groups
hUCM dhUCM
p < 0.05
p < 0.05
p < 0.05
LVEF Day 5
LVEF Day 30
p < 0.05
 Fig. 4. The animals in the hUCM and dhUCM groups demon-
strated a significant improvement in LVEF compared to the MI 
and PBS groups. Results obtained 5 and 30 days after LAD liga-
tion. A significant change in LVEF was detected when LVEF 
change in hUCM and dhUCM groups was compared to other 
groups. Bars are representative of means  8 SEM. 
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and rapidly expanded in laboratory, immunologically 
compatible and capable of long-term survival and inte-
gration in the host tissue. hUCM cells can be easily ob-
tained and harvested, compared to bone marrow mesen-
chymal stromal cells. These cells have greater colony-
forming unit fibroblast frequency and shorter doubling 
time compared with bone marrow mesenchymal stromal 
cells  [24] . In the present study, we used a nonenzymatic 
method which yielded a sufficient number of cells after 
two weeks of culture. Isolated cells formed alkaline phos-
phatase-positive colonies in plastic dishes and hanging 
drops, a feature common to embryonic stem cells  [25] . 
100 µm
100 µm
100 µm
100 µm
100 µm
100 µm
a b
c d
e f
tc
nm
tc
nm
 Fig. 5. BrdU-positive cells were found in 
the transplanted area ( a ). HNA-positive 
cells (green), DAPI-positive cells (blue) 
and a merged image of them (light blue) 
are shown in the infarcted area ( b ). Anti-
troponin-I staining revealed troponin-I+ 
cells both in normal myocardium (filled 
arrows) and in engrafted area (encircled 
zone; hollow arrows) ( c ,  d ). Double stain-
ing showed BrdU+/troponin-I+ cells (ar-
rowheads) between transplanted cells (tc); 
normal myocardium (nm, arrows) was 
positive for troponin-I ( e ,  f ). Colors refer 
to the online version. 
Table 2. H istopathologic findings of the treatment groups (n = 7)
Parameter Sham PBS hUCM dhUCM
Chronic inflammation (0–3) 1.2880.18 0.680.3 0.8680.14 1
Small vessels 9.1483.15 9.9186.81 8.5783.70 6.4382.37
Lymphocytes 18.9088.2 14.5782.8 17.1487.5 22.14817.3
Scar tissue (0–3) 2.2980.42 1.4680.49 0.7180.35* 0.5780.3**
Fibroblasts 307860.2 198862.3 89844.7 77832.2
V alues are representative of means 8 SEM. * p = 0.056; ** p = 0.042 versus the sham group. 
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These cells also successfully differentiated into adipo-
cytes and osteocytes in vitro.
 After cardiogenic differentiation, some dhUCM cells 
transformed into binucleate cells with extensive cytoplas-
mic processes, a common feature of cardiac cells. These 
cells expressed F-actin and myogenin. However, tropo-
nin-I expression, as a cardiac marker, was not detected in 
this study, nor was it confirmed after myogenic differen-
tiation in vitro in human bone marrow stem cells  [5, 26] . 
Presence of troponin-I- and connexin43-positive cells 
between the transplanted cells in the MI area and in the 
remote distance from it suggests that cardiac milieu has 
induced cardiogenic differentiation in the transplanted 
cells. Exposure of hUCM cells to a cardiomyocyte-condi-
tioned medium has also resulted in differentiation of 
these cells into troponin-I- and N-cadherin-positive cells 
 [19] . 
 In this study, transplantation of hUCM and dhUCM 
cells improved LV function with no significant differ-
ence. However, a slight nonsignificant increase in LVEF 
was detected in dhUCM group compared with hUCM 
group ( fig. 2 b). Although the hUCM cells differentiated 
into cardiomyocyte-like cells by 5-azacitidine, dhUCM 
cells have improved LV function at a comparable rate 
with the hUCM cells. Gap junctions as the functional 
unit of grafted cells were also expressed in the both 
groups. Such results have been reported after treatment 
of MI-induced animals with differentiated and nondif-
a b
c d
e f
100 µm100 µm
100 µm 100 µm
100 µm 50 µm
 Fig. 6. Hematoxylin-eosin staining dem-
onstrated more scar tissues in the MI and 
PBS groups ( a ; asterisks); while in hUCM- 
and dhUCM-treated myocardium ( b ; hol-
low stars) fibrous tissue was less abundant. 
Bundles of myocardium were interposed 
between transplanted cells ( c ; arrows). 
Some transplanted cells were F-actin posi-
tive ( d ; small arrows) and few vessel-like 
structures ( d ; hollow arrow) were also 
present adjacent to the transplanted area. 
The transplanted cells were found at the 
transplantation site and remote from it ( e ). 
A merged image of immunostaining 
against connexin43 showed connexin43-
positive cells in the transplanted area ( f ; 
arrowhead), at the interphase (arrows) and 
host myocardium (stars). 
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ferentiated UCB cells  [12] . The precise mechanism by 
which the transplanted cells may contribute to the regen-
eration of MI heart is unknown yet. There are several 
potential explanations. One possible reason is that stem 
cells differentiate into myogenic-like cells; if the trans-
planted cells are in contact with the contracting host 
myocardium, myocardial factors from the host myocar-
dium might induce the engrafted cells to differentiate 
into myogenic-like cells, that is, the hypothesis of ‘mi-
lieu-influenced’ differentiation  [22] . Another reason is 
that engrafted cells may fuse to cardiomyocytes in the 
normal myocardium to trigger the reentry of fused car-
diomyocytes into a functional state  [27] . We could dem-
onstrate that some engrafted cells next to the host myo-
cardium and remote from the injection site had stained 
positively with troponin-I and F-actin and connexin43 
( fig.  5 ,  6 ) as cardiac, mesenchymal and gap junction 
markers, respectively. Lack of specific detection systems 
to demonstrate contractile function in transplanted cells 
at present has limited our ability to finally state that
hUCMs implanted in the damaged myocardium could 
actually differentiate and function as a cardiomyocyte. 
Another mechanism which has been proposed to explain 
the beneficial influence of stem cells in cardiac repair is 
the secretion of growth factors and cytokines by trans-
planted cells to induce myogenic differentiation of trans-
planted cells and/or mobilization, homing and differen-
tiation of host stem cells into myocytes  [28] . hUCMs se-
crete CXCR4, the receptor for stem cell-derived factor 1 
 [10] . Local injection of SCF improved myocardial homing 
of systemically derived bone marrow stem cells  [29] . Al-
though we could detect some viable troponin-I- and F-
actin-positive cells adjacent to and between the injured 
myocardium, the small number of BrdU+/troponin-I+ 
cells may not explain the overt improvement of LVEF
in cell-transplanted groups. Therefore, we suggest that 
mechanisms other than transdifferentiation to cardio-
myocytes should have been involved in myocardial repair 
following hUCM and dhUCM cell transplantation.
 Potentially, stem cells could alter collagenase activity 
or other enzymatic pathways responsible for pathologic 
heart wall thinning in injured myocardium, resulting in 
digestion of scar tissues and modification of extracellular 
matrix proteins  [30] . Overexpression of collagen type I 
and III may protect infarcted myocardium from remod-
eling and dilation, but the increase in collagen synthesis 
in myocardium could result in stiffness and dysfunction 
of the damaged heart. In our study, the number of fibro-
blasts and also the scar tissue decreased in the cell-trans-
planted groups in comparison with those in the MI and 
PBS groups. Consequently, the functional improvement 
in cell-treated hearts could also be explained by the po-
tential of the transplanted hUCM cells to reduce scar tis-
sue and to increase more viable functional tissues to sup-
port damaged heart function. These results are support-
ed by a recent study in which doxorubicin-induced 
cardiac hypertrophy was corrected after transplantation 
of human UCB cells in mice  [31] .
 Mesenchymal stromal cells have a relatively immuno-
privileged phenotype; lack of HLA-class-II antigens en-
ables them to survive and reside in an inflammatory mi-
lieu without activating the immune system. Similarly to 
MSCs, hUCM cells express HLA-class-I and do not express 
HLA-class-II surface markers  [32] . A recent study has 
shown that when a single dose of umbilical cord cells from 
4 MGH MHC-defined miniature swine leukocyte antigen 
(SLA)dd was injected to MHC-mismatched SLAcc and 
SLAac animals, the cell-treated animals failed to demon-
strate any detectable level of serum antibody production of 
IgG directed towards SLAdd cells after one month  [33] . We 
used cyclosporine A to suppress probable immune re-
sponses in the host animals. However, in one animal en-
grafted with hUCM cells and without cyclosporine A in-
jection, no histopathologic sign of tissue rejection was de-
tected (data not shown). Other researchers have implanted 
hUCM cells as xenografts and reported that such a proce-
dure did not alleviate immune response in the host ani-
mals  [18] . Nonimmunogenic nature of these cells proposes 
them as an alternative and valuable candidate for cell ther-
apy in degenerative heart diseases. However, some debates 
remain to be elucidated before these cells could be utilized 
in clinical studies. The safety of hUCM cells as a homo-
graft tissue, long-term survival, optimal cell dose, the most 
effective route of delivery, potentiality of hUCM cells in the 
treatment of different types of heart failure and the ability 
of hUCM cells in the treatment of ischemic myocardium 
compared with other cell types are yet unclear.
 Conclusion 
 The hUCM cells may be considered an alternative cell 
source to repair the damaged myocardium after MI. 
These cells could differentiate into myocyte-like cells un-
der influence of 5-azacytidine. Transplantation of hUCM 
cells clearly improves left ventricular function 30 days 
after transplantation at a similar rate to dhUCM cells. 
Furthermore, there is convincing evidence that hUCM 
cells are involved in the scar tissue remodeling during 
healing process after MI. 
 Latifpour et al. Cardiology 2011;120:9–1818
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